Response surface methodology-assisted development of an eco-friendly HPLC-UV method for the simultaneous determination of Ruxolitinib and Levofloxacin in plasma: Application to pharmacokinetic studies and drug-drug interactions in rats
Acta Chromatographica · 28.07.2026
DOI: 10.1556/1326.2026.01513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Chromatographica, erschienen am 28.07.2026. Verfasst von Amsha S. Alsegiani und 5 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Ruxolitinib (RUX) is the first JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Due to its immunosuppressive activity, levofloxacin (LEV) is often co-prescribed with RUX to treat infections in patients undergoing chemotherapy. This combination can alter the pharmacokinetics of RUX and lead to potential drug-drug interactions. To refine these effects, an efficient analytical tool is needed to determine the concentrations of RUX and LEV in blood simultaneously. Regrettably, such a method for the simultaneous determination of RUX and LEV does not exist in the literature. This study introduces the first HPLC method with UV detection for the simultaneous quantification of RUX and LEV in plasma. Response surface methodology was used to optimize and refine variables affecting the chromatographic conditions. Optimized procedures for the HPLC-UV method were established. The method exhibited linearity over the concentration ranges of 20–2,500 and 30–4,000 ng mL −1 for RUX and LEV, respectively. Following the ICH guidelines for bioanalytical method validation, all method validation parameters were satisfactory. The limits of quantification were determined and found to be 20 and 30 ng mL −1 for RUX and LEV, respectively. The accuracy of the method ranged from 96.10 to 100.16% for RUX and from 96.73 to 99.31% for LEV, and its precision did not exceed 3.60 and 1.87% for RUX and LEV, respectively. The eco-friendliness of the method was confirmed through three comprehensive tools. The method was successfully employed to study the pharmacokinetics and drug-drug interactions of RUX and LEV in rats after single oral doses. The results demonstrated that their co-administration substantially altered the pharmacokinetics of both drugs, and caution is warranted with RUX dosing when co-administered with LEV. In conclusion, this method represents a valuable tool for determining the optimal dosage and dosing regimen for RUX in combination therapy with LEV, aiding in pharmacokinetic/bioavailability studies and therapeutic drug monitoring during MF therapy.
Förderung
- King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Alsegiani, A. S., Alrubia, S., Herqash, R. N., Ali, A. M., Alsalhi, M. S., & Darwish, I. A. (2026). Response surface methodology-assisted development of an eco-friendly HPLC-UV method for the simultaneous determination of Ruxolitinib and Levofloxacin in plasma: Application to pharmacokinetic studies and drug-drug interactions in rats. Acta Chromatographica. https://doi.org/10.1556/1326.2026.01513
Vancouver
Alsegiani AS, Alrubia S, Herqash RN, Ali AM, Alsalhi MS, Darwish IA. Response surface methodology-assisted development of an eco-friendly HPLC-UV method for the simultaneous determination of Ruxolitinib and Levofloxacin in plasma: Application to pharmacokinetic studies and drug-drug interactions in rats. Acta Chromatographica. 2026. doi:10.1556/1326.2026.01513
BibTeX
@article{Alsegiani2026,
author = {Alsegiani, Amsha S. and Alrubia, Sarah and Herqash, Rashed N. and Ali, Awadh M. and Alsalhi, Mohamed S. and Darwish, Ibrahim A.},
title = {Response surface methodology-assisted development of an eco-friendly HPLC-UV method for the simultaneous determination of Ruxolitinib and Levofloxacin in plasma: Application to pharmacokinetic studies and drug-drug interactions in rats},
journal = {Acta Chromatographica},
year = {2026},
doi = {10.1556/1326.2026.01513}
}
EUVIMED